Israeli multinational pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced on Wednesday that the US Food and Drug Administration has approved AJOVY (fremanezumab-vfrm) for the preventive treatment of episodic migraine in children and adolescents aged 6–17 years who weigh at least 45 kilograms.

This makes AJOVY the first calcitonin gene-related peptide (CGRP) antagonist indicated for both paediatric episodic migraine prevention and adult migraine prevention.

AJOVY is administered as a once-monthly injection, available for in-office or at-home use, aiming to support treatment adherence and reduce burden on families. Preventive therapy can help decrease the frequency of migraine attacks, enabling better day-to-day management for young patients.

According to Teva, one in ten children and adolescents in the US suffers from migraine, a condition that is often under-recognised and undertreated. This can lead to missed school days, academic difficulties, and social disruptions.

Teva highlighted that this expanded indication builds on AJOVY's established success in adults since its US approval in 2018 and underscores the company's commitment to broadening access to therapies across age groups.